February 25, 2018
LexaGene grants compensation awards, pursuant to the Company's Omnibus Incentive Plan to employees, officers, and directors of the company.
February 13, 2018
LexaGene appoints Nathan Walsh to Director of Applications - Bioinformatics and Manoj Nair to Senior Staff Scientist.
February 6, 2018
LexaGene leases larger space to support company growth. The Company has significantly expanded its operations and made key new hires.
January 25, 2018
LexaGene appoints Greg Dale to Vice President of Product Development and Manufacturing, bringing strong tech product commercialization experience to the company.
January 22, 2018
LexaGene is pleased to announce over-allotment option in connection with the closing of the Company’s bought deal financing previously announced.
December 19, 2017
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 19, 2017 (GLOBE NEWSWIRE) -- LexaGene…
December 4, 2017
LexaGene announces that it has filed an amended annual information form for the year ended February 28, 2017 (the “Amended AIF”).
November 30, 2017
LexaGene completes prototype assembly for soon-to-be first fully automated, open-access pathogen detection system.
November 28, 2017
LexaGene Holdings Inc. announces C$5.0 million bought deal led by Canaccord Genuity Corp.
October 12, 2017
LexaGene wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.
For Marketing inquiries, please email:
info@lexagene.com
800-215-1824